About Progenics
Progenics is a company based in United States founded in 1988 was acquired by Lantheus in October 2019. The company has 53 employees as of December 31, 2020. Progenics has completed 3 acquisitions, including AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals. Progenics operates in a competitive market with competitors including ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.
- Headquarter United States
- Employees 53 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Progenics Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Progenics
Unlock access to complete
Funding Insights of Progenics
Investors in Progenics
Progenics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Lantheus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Developer of diagnostic imaging agents and targeted therapeutics
|
Locked | Locked | Locked |
Investor details for Progenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Progenics
Progenics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals.
Investment portfolio details for Progenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapy for pheochromocytoma and paraganglioma diseases is provided.
|
Locked | Locked | 2006 | Locked | |
|
Artificial neural networks are applied to medical scan diagnostics.
|
Locked | Locked | 1999 | Locked | |
|
Radiopharmaceuticals and molecular imaging agents for use in oncology
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Progenics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Progenics
Detailed financials for Progenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Progenics Comparisons
Peer comparison for Progenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Progenics
Progenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Epigenetic tests for personalized cancer assessment and treatment.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Genomic tests for urologic cancers are developed and commercialized.
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs and imaging agent for GI disorders
|
Detailed competitors of Progenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Progenics
Complete news archive for Progenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Progenics
Progenics was founded in 1988 and raised its 1st funding round 18 years after it was founded.
Progenics is headquartered in United States.
As of Dec 31, 2020, the latest employee count at Progenics is 53.
Progenics Pharmaceuticals was founded in 1988 in the United States and operates in the oncology sector of pharmaceuticals. Imaging agents and targeted radiotherapeutics are developed, focusing on prostate-specific membrane antigen (PSMA)-targeted technologies for prostate cancer, including antibody drug conjugates and small molecule agents. Additional pipeline assets include Azedra for malignant pheochromocytoma and paraganglioma treatment. The first commercial product, Relistor, is approved for opioid-induced constipation.
Progenics has made 3 acquisitions, including AZEDRA, EXINI Diagnostics, and Molecular Insight Pharmaceuticals.